5-alpha reductase inhibitors associated with reduced risk of incidental prostate cancer in surgical patientsCertain factors linked to finding prostate cancer during surgery

This meta-analysis evaluated the clinical predictors of incidental prostate cancer (IPC) in a large cohort of 247,966 patients undergoing surgery for benign prostate enlargement. The study aimed to identify specific factors, including laboratory values, patient demographics, and pharmacological interventions, that correlate with the detection of undiagnosed prostate cancer during surgical procedures.

The primary analysis focused on the identification of IPC, where 6,748 patients were identified with the condition. The study evaluated several predictors: PSA level, PSA density, age, body mass index (BMI), and the use of 5-alpha reductase inhibitors (5-ARIs). The study also assessed secondary outcomes including prostate volume, diabetes, and dyslipidemia to determine their relationship with IPC risk.

Several significant associations were identified regarding IPC risk. Elevated PSA levels were associated with a higher risk of IPC (OR: 1.03; 95% CI: 1.01-1.05; p = 0.01). PSA density greater than 0.15 ng/mL/cc showed a significantly higher risk (OR: 3.02; 95% CI: 1.50-6.07; p = 0.01). Patient age was also a significant factor, with older age associated with higher risk (OR: 1.05; 95% CI: 1.01-1.08; p = 0.01). Additionally, a higher body mass index (BMI) was associated with an increased risk of IPC (OR: 1.10; 95% CI: 1.02-1.18; p = 0.01).

Notably, the use of 5-alpha reductase inhibitors (5-ARIs) was associated with a reduced risk of IPC (OR: 0.53; 95% CI: 0.33-0.85; p = 0.01). In contrast, secondary outcomes including prostate volume, diabetes, and dyslipidemia were not associated with IPC risk. No specific data regarding safety, tolerability, or adverse events were reported in the analysis.

These findings contribute to the understanding of risk stratification in patients with benign prostate enlargement. While the study identifies 5-ARIs as a factor associated with lower IPC risk, it is important to note that these results are based on observational and retrospective data. The study also noted several limitations, including heterogeneity across the included studies, the use of retrospective designs, and incomplete reporting of key variables. The certainty of these findings was not reported.

Clinically, these results may support improved preoperative risk stratification. Identifying patients with higher risk factors, such as high PSA density or advanced age, may help clinicians determine which patients require more intensive diagnostic evaluations before surgery. Conversely, the association between 5-ARIs and lower IPC risk may provide insights into the role of these medications in the clinical landscape of benign prostate enlargement. However, the lack of a clear causal link due to the study design means these findings should be interpreted as associations rather than definitive evidence of prevention. Questions remain regarding the specific mechanisms by which 5-ARIs influence IPC detection and the impact of these findings on standard surgical protocols.